Breast Cancer Screening Market  By Test Type (Blood Marker Test, Genetic Test, Imaging Test, Immunohistochemistry Test) , By Gender (Male, Female) By End User (Specialty Clinics, Hospitals, Diagnostic Centers, Other) : Global Opportunity Analysis and Indu

Breast Cancer Screening Market  By Test Type (Blood Marker Test, Genetic Test, Imaging Test, Immunohistochemistry Test) , By Gender (Male, Female) By End User (Specialty Clinics, Hospitals, Diagnostic Centers, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033

The breast cancer screening market was valued at $2.9 billion in 2023, and is projected to reach $6.7 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Breast cancer screening is a critical public health strategy aimed at early detection of breast cancer, the most common cancer among women globally. The primary goal of this preventative measure is to identify cancer at an early stage when it is most treatable. Mammography is the most widely used screening tool, and its regular use has been shown to reduce mortality rates from breast cancer. By detecting tumors early, breast cancer screening increases the chances of successful treatment, improves survival rates, and can help to reduce the need for more aggressive treatments later on.
The growth of the global breast cancer screening market is driven by alarming increase in the global prevalence of breast cancer and rise in awareness and demand for early detection methods. According to a study published in March 2024 by the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer and 670,000 deaths were reported globally in 2022. Furthermore, governments and healthcare organizations are increasingly promoting breast cancer screening through awareness campaigns, subsidies, and organized screening programs, which have encouraged easy access to screening services. According to a study published by the U.S. Centers for Disease Control and Prevention in 2022, approximately 76.4% of women aged 50-74 underwent a mammogram within the past two years. This statistic reflects the effectiveness of public health campaigns and the accessibility of screening services across the U.S. Moreover, surge in aged women population significantly contributes toward the market growth. This is attributed to the fact that aged women are at higher risk of developing breast cancer due to weakened immune system, accumulation of genetic mutations, and changes in breast tissue. Rise in emphasis on early screening in younger women and development of non-invasive screening methods are the key trends are that further fostering the market growth. However, high cost associated with breast cancer screening, particularly advanced technologies like 3D mammography or MRI, acts as a key deterrent factor of the global market. In addition, limited access in rural and underserved areas due to lack of healthcare infrastructure, trained professionals, and mobile screening units significantly restrains the market growth. On the contrary, innovations in imaging technologies, such as digital mammography, 3D mammography, and MRI, are enhancing the accuracy and efficiency of breast cancer screening. These advancements are making screening more accessible and reliable, which are expected to offer remunerative opportunities for the expansion of the global market during the market. To improve access to breast cancer screening in remote and underserved areas, mobile mammography units are being introduced to address the concern of limited access to healthcare. Such initiatives are anticipated to open new avenues for the market growth in the near future.
The global breast cancer screening industry is segmented into test type, gender, end user, and region. By test type, the market is divided into blood marker test, genetic test, imaging test, and immunohistochemistry test. According to gender, it is divided into male and female. As per end user, it is fragmented into specialty clinics, hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By test type, the imaging test segment dominated the market share in 2023.
According to gender, the female segment exhibited the largest market share in 2023.
As per end user, hospital emerged as the leading segment, in terms of share, in 2023.
Region wise, North America holds a dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global breast cancer screening market include Siemens Healthineers AG, Myriad Genetics, Inc., Metabolomic Technologies Inc, Biocrates Lifesciences AG, A&G Pharmaceutical, Provista Diagnostics Inc, F. Hoffmann-La Roche AG, Volpara Health Limited, Quest Diagnostics Inc., and GE Healthcare. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Key Market Segments

By Test Type

Blood Marker Test
Genetic Test
Imaging Test
Immunohistochemistry Test

By Gender

Male
Female

By End User

Specialty Clinics
Hospitals
Diagnostic Centers
Other

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Siemens Healthineers AG
Myriad Genetics, Inc.
Metabolomic Technologies Inc
Biocrates Lifesciences AG
A&G Pharmaceutical
Provista Diagnostics Inc
F. Hoffmann-La Roche AG
Volpara Health Limited
Quest Diagnostics Inc.
GE Healthcare